Literature DB >> 8206495

Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

T Boon1, P Coulie, M Marchand, P Weynants, T Wölfel, V Brichard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8206495

Source DB:  PubMed          Journal:  Important Adv Oncol        ISSN： 0883-5896


× No keyword cloud information.
  9 in total

Review 1.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

Review 2.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

Authors:  Y Zhai; J C Yang; P Spiess; M I Nishimura; W W Overwijk; B Roberts; N P Restifo; S A Rosenberg
Journal:  J Immunother       Date:  1997-01       Impact factor: 4.456

4.  Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.

Authors:  A Porgador; O Mandelboim; N P Restifo; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.

Authors:  H Büeler; R C Mulligan
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

6.  Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.

Authors:  D Schadendorf; B M Czarnetzki; B Wittig
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

Review 7.  Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.

Authors:  V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Specific increase in potency via structure-based design of a TCR.

Authors:  Karolina Malecek; Arsen Grigoryan; Shi Zhong; Wei Jun Gu; Laura A Johnson; Steven A Rosenberg; Timothy Cardozo; Michelle Krogsgaard
Journal:  J Immunol       Date:  2014-07-28       Impact factor: 5.422

9.  Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.

Authors:  S Saitoh; M Kurisaka; K Mori; N Maeda; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1997-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.